DOCSLIB.ORG

The Abbvie Experience • Business Overview • Talent Practices Welcome to • Our Culture Abbvie! • Company Resources • Rewards & Benefits

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Abbvie Experience • Business Overview • Talent Practices Welcome to • Our Culture Abbvie! • Company Resources • Rewards & Benefits The AbbVie Experience • Business Overview • Talent Practices Welcome to • Our Culture AbbVie! • Company Resources • Rewards & Benefits ©2020 | Confidential | Do not distribute 2 AbbVie has as long history in healthcare dating back to 1888 with Abbott 130+ years of patient care Launched as AbbVie in 2013 Millions of lives touched ©2020 | Confidential | Do not distribute 3 The AbbVie Way ©2020 | Confidential | Do not distribute 4 Vision To be recognized as a biopharmaceutical company delivering a consistent stream of innovative medicines that solve serious health issues and have a remarkable impact on people’s lives. ©2020 | Confidential | Do not distribute 5 Our Principles Transforming Lives Acting with Integrity Driving Innovation Embracing Diversity & Inclusion Serving the Community ©2020 | Confidential | Do not distribute 6 A compelling growth story 2013 2014 2015 2016 2017 2018 On January 2, 2013, we AbbVie brands surpass We brought We expanded our We closed the year We exemplified our marked our first official 30 million patients Pharmacyclics into the neuroscience research with the #2 spot on culture of giving back, day as a new impacted around the AbbVie family and – including Alzheimer’s Barron’s 500. donating $350 million biopharmaceutical world and our first expanded our disease – with the to support U.S. company AbbVie-created commitment to opening of our 43,000- nonprofits. medicine is approved. identifying novel square-foot Cambridge treatments for cancer. Research Center in Massachusetts. ©2020 | Confidential | Do not distribute 7 2020 Priorities ©2020 | Confidential | Do not distribute 8 Therapeutic areas of focus • Immunology • Oncology • Neuroscience • Virology • Eye Care • Other Specialties • Gastroenterology • Cardiology • General Medicine • Women’s Health • Allergan Aesthetics ©2020 | Confidential | Do not distribute 9 AbbVie Products ©2020 | Confidential | Do not distribute 10 With Allergan, AbbVie has an expanded global footprint of state-of-the-art facilities Ireland: Ballytivnan Cork Sligo Ireland: Dublin Michigan, USA Galway Illinois, USA: Wyandotte Lake County Westport North Chicago New Jersey, USA: Branchburg Ludwigshafen, Germany California, USA: Madison Redwood City Massachusetts, USA: Marlow, United Kingdom San Francisco Cambridge Sunnyvale Worcester Pringy, France California, USA: Cincinnati, OH, USA Campbell Grâce-Hollogne, Belgium Dublin/Pleasanton Barceloneta, Irvine Puerto Rico (2) Campoverde, Italy Texas, USA: Houston Tokyo, Japan Waco Singapore, Singapore Heredia, Costa Rica Grande Guarulhos, Brazil AbbVie facilities Allergan facilities *Not all sites pictured We have market leadership in attractive growth segments #1 #2 Immunology Hematologic oncology Leadership in Women’s #1 health Aesthetics Leadership in #1 Eye care Global HCV ©2020 | Confidential | Do not distribute 12 External Recognition As a Top Company Workplace & Diversity Environment, Social and Citizenship Business Performance Governance DiversityInc. “Top 50 Companies for Civic 50 FORTUNE 100 Diversity” Dow Jones Sustainability World Index Corporate Responsibility Magazine’s FORTUNE World’s Most Admired FORTUNE “100 Best EcoVadis Corporate Social “100 Best Corporate Citizens” Companies Companies to Work For” Responsibility Assessment Gold Medal Great Places to Work “World’s Best FORTUNE/Great Places to Work Pharma Reptrak Most Reputable Workplaces” “Best Workplaces for Giving Back” Companies FTSE4Good Index Human Rights Campaign Corporate PEOPLE’s “50 Companies That Equality Index Care” S&P 500 ESG Index Science Magazine’s Top Employers Working Mother “100 Best Companies” *Most recent accolades as of 2019 ©2020 | Confidential | Do not distribute 13 Talent Practices ©2020 | Confidential | Do not distribute 14 Talent Philosophy ©2020 | Confidential | Do not distribute 15 Talent Philosophy Definitions Performance: We push ourselves and each other to reach high levels of performance to best serve our patients. Behaviors: We demonstrate the behaviors critical to driving AbbVie’s future performance and expect the same of our teams. Differentiation: We hold ourselves and each other to the highest standard and ensure that those employees who make the greatest contributions receive the greatest rewards. Accountability: We are each accountable for how we perform. Our leaders are also accountable for developing our people in ways that drive performance and support our culture. Transparency: We are honest and provide feedback to employees about their performance and future within the organization; what it takes to succeed and win at AbbVie. ©2020 | Confidential | Do not distribute 16 Raise the Bar: Talent Philosophy in Action 1 2 3 Set Expectations Observe and Coach Calibrate and Assess DECEMBER 1 – JANUARY 31 ALL YEAR YEAR END Focus each employee on three Actively guide employees to Assess employee performance; to five highly challenging goals; achieve higher performance; take results and behaviors. and one learning objective. Time to Talk in Q2 and Q3. People Leaders are accountable for driving "Raise the Bar" ©2020 | Confidential | Do not distribute 17 Our Culture ©2020 | Confidential | Do not distribute 18 The Ways We Work Driving Our Culture ©2020 | Confidential | Do not distribute 19 All For One AbbVie Core Leadership Attributes • Operates with an enterprise perspective, putting overall AbbVie before individual or functional interests. • Inspires and motivates others toward a shared purpose. • Influences colleagues to achieve cross-functional alignment. • Manages inclusively and equitably across all. We weigh all decisions against the common good. People Leader Attributes We inspire, share and create as a team. We solve • Selects and builds diverse, high-performing teams. problems for all rather than • Creates an inclusive environment where all direct serving our immediate team. reports can succeed. ©2020 | Confidential | Do not distribute 20 Decide Smart & Sure Core Leadership Attributes • Deals comfortably with risk and ambiguity, changing course when needed. • Knows the business and the cross-functional contribution needed to deliver results. • Makes timely, high-quality decisions with less than perfect information. • Lives AbbVie principles. Acts consistently with our ethics, obligations and the law. We make intelligent decisions to create the best People Leader Attributes outcomes. We act quickly, embrace experimentation, • Recognizes and rewards direct reports for the and learn what doesn’t work results produced. and get on to what does. • Deals with behavior and performance issues that do not meet AbbVie expectations in an appropriate and timely way. ©2020 | Confidential | Do not distribute 21 Agile & Accountable Core Leadership Attributes • Sets clear strategies and robust implementation plans. • Gives full accountability when delegating; accepts full accountability when delegated to by others. • Delivers business results while also positioning AbbVie for long term success. • Simplifies how work gets done; removes needless bureaucracy. We streamline and eliminate unnecessary obstacles. We People Leader Attributes plan but adapt as we go. We delegate and make tough • Sets clear goals that challenge direct reports to decisions to ensure focus on raise the bar on performance. results, staying keenly aware • Enables direct reports to adapt and move fast. of the urgency in all we do. ©2020 | Confidential | Do not distribute 22 Clear & Courageous Core Leadership Attributes • Acts respectfully yet courageously; says what needs to be said. • Manages conflict and difficult conversations in a constructive, transparent way. • Uses mistakes, failure and reflection as vehicles for learning and improvement. • Communicates openly and honestly with all colleagues. Open, honest, candid dialogue is core to our work and how we People Leader Attributes act with each other. We share information freely and • Respectfully provides transparent, accurate and continuously to find solutions. timely feedback to help direct reports improve We admit mistakes. We grow performance. stronger by putting the courage • Generates confidence and momentum through of our conviction to the test. times of change. ©2020 | Confidential | Do not distribute 23 Make Possibilities Real Core Leadership Attributes • Looks outside AbbVie for new ideas to stimulate innovation. • Connects unrelated concepts; generates original or unique ideas. • Creates an environment in which people appropriately experiment and challenge the status quo. • Finds ways to move good ideas forward through persistence and resilience. We question with endless curiosity. We’re never satisfied People Leader Attributes with good enough—patients depend on us to deliver more. • Develops direct reports and capable successors We challenge ourselves to find through coaching, stretch assignments and learning creative, constructive solutions opportunities. to turn possibilities into reality. • Removes obstacles and provides support that enables direct reports to achieve results. ©2020 | Confidential | Do not distribute 24 TRIVIA ©2020 | Confidential | Do not distribute 25 While never compromising patient health or safety, we act quickly, not allowing pace to be the captive of perfection. ©2020 | Confidential | Do not distribute 26 While never compromising patient health or safety, we act quickly, not allowing pace to be the captive of perfection. ©2020 | Confidential | Do not distribute 27 Embracing ideas from everywhere, we have the patience to let them develop, even as we push for results. ©2020 | Confidential
Load more

Recommended publications
  • Abbvie Allergan Acquisition
    Creating a New Diversified Biopharmaceutical Company The Combination of AbbVie and Allergan Investor Presentation June 25, 2019 NO OFFER OR SOLICITATION This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this presentation is not an offer of securities for sale into the United States. No offer of securities shall be made in the United States absent registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued in the acquisition are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act of 1933, as amended. The acquisition will be made solely by means of the Scheme Document (or, if applicable, the Takeover Offer document), which will contain the full terms and conditions of the acquisition, including details with respect to the AbbVie shareholder vote in respect of the acquisition. Any decision in respect of, or other response to, the acquisition, should be made only on the basis of the information contained in the Scheme Document. IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC In connection with the proposed Acquisition, Allergan will file with the Securities Exchange Commission (the “SEC”) a Proxy Statement, which will include the Scheme Document.
    [Show full text]
  • Overcoming Jury Bias
    OVERCOMING JURY BIAS The purpose of this paper is to examine various approaches to coping with biases, beliefs and preloaded conceptions, particularly regarding the civil justice system, which citizens bring to the courthouse when called for jury duty. We overlay modern forensic psychological princi- ples which have emerged from numerous studies of the decision-making processes of jurors onto persuasive techniques which have been used successfully for centuries. Finally, we examine twelve suggested methods to cope with jury bias. We also examine methods of creating, struc- turing and testing messages and themes as well as techniques for effective delivery of themes as a means of assisting jurors in setting aside bias. However, we begin where all persuasion begins: with Aristotle. I. ARISTOTLE'S PRINCIPLES OF PERSUASION 2300 years ago, Aristotle, in his Discourse on Rhetoric reduced the principles of argu- ment to four major points. Examination of these four points reveals that they serve those of us who labor in the vineyards of litigation as well today as they have served Aristotelian scholars for 23 centuries. Aristotle's first principle: Well dispose your audience to you and ill dispose them to your enemy. It is not sufficient to make your own case but it is also necessary to affirmatively attack your opponent's position, particularly on their most salient points. We often win the battle on the case in chief and lose the war through ignoring the opponent's case. Ideally, co-counsel in your office should be assigned the task of preparing fully the other side's case from their perspective.
    [Show full text]
  • Faculty Disclosure
    Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role AbbVie, Allergan/ Tobira Therapeutics Inc, Gilead Research Grant Research Balart Sciences Inc, Pfizer, Salix Pharmaceuticals AbbVie, Merck Honorarium Advisory Board Bau None N/A N/A Benz None N/A N/A AbbVie, Arbutus Biopharma, Dieterich Gilead Sciences, Inc., Bristol- Research Grant Consultant Myers Squibb, Merck Bayer HealthCare Pharmaceuticals, Gilead Sciences Honorarium Speaking, Consultant Inc. Bristol-Myers Squibb, Gilead Speaking, Advisory Sciences, Inc, Salix Honorarium Frenette Board Pharmaceuticals, Inc, Merck Intercept Pharmaceuticals Honorarium Advisor Conatus Pharmaceuticals Inc Honorarium Consulting Principle Investigator, Research Grant, Han Gilead Sciences,
    [Show full text]
  • Jury Selection in Federal Court
    Resource ID: 1-613-5747 Jury Selection in Federal Court JONATHAN S. TAM, DECHERT LLP, WITH PRACTICAL LAW LITIGATION Search the Resource ID numbers in blue on Westlaw for more. This Practice Note addresses selecting a jury Exercising juror challenges (see Exercising Juror Challenges). in a federal civil case, including the applicable Conducting post-trial interviews (see Conducting Post-Trial Interviews). rules on picking a jury, the process and method for jury selection, researching prospective OVERVIEW OF THE JURY SELECTION PROCESS jurors and building juror profiles, conducting Although how a jury is selected varies among courts and judges, the voir dire, exercising peremptory challenges, process in federal court generally occurs in the following order: The court may first mail a preliminary, administrative questionnaire challenges for cause, and Batson challenges, to a randomly selected pool of prospective jurors from registered and interviewing jurors post-trial. voter or licensed driver lists to determine if these individuals appear qualified for federal jury service based on their age and ability to understand English (see Juror Qualifications). The prospect of a jury trial often keeps counsel and their clients The court mails summonses to an initial pool of randomly selected awake at night. Juries can be unpredictable, and jurors may have prospective jurors. The court then randomly selects a narrower preconceived ideas or biases that can escape counsel during the pool of prospective jurors from the initial pool, and calls them for a selection process. Some cases may be won or lost during jury specific case. selection, before opening statements or a single piece of evidence The judge presiding over the case determines whether any jurors is introduced.
    [Show full text]
  • The Covid–19 Pandemic and Haemoglobin Disorders
    THE COVID–19 PANDEMIC AND HAEMOGLOBIN DISORDERS VACCINATIONS & THERAPEUTIC DRUGS An Informational Guide from the Thalassaemia International Federation (TIF) Prepared by: Dr Androulla Eleftheriou, Executive Director, TIF Last Updated: 12 May 2020 VACCINATIONS & THERAPEUTIC DRUGS Introduction It is important to note that there are currently no FDA1 or EMA2-approved or even recommended agents for the treatment of the novel coronavirus (COVID-19), for which the World Health Organization (WHO) declared as pandemic on Wednesday 11th of March 2020. Any agent being used at this time is being administered in an experimental setting under controlled conditions. Thalassaemia International Federation (TIF) has made an effort to compile a list of studies/clinical trials for treatment and vaccines, which is by no means exhaustive as this situation is extremely labile and research in this area is dramatically intensified. New information is anticipated to be added to this guide which is prepared exclusively for TIF’s global thalassemia community. The viral genome was mapped very soon as rom early January 2020 and shared globally. In February 2020, the WHO published an overview of the potential therapeutic candidates for the treatment of COVID-19. The document outlines 76 regimens that have been proposed (as of February 17, 2020) for the treatment of patients infected with the virus. Thirty-eight of these candidates are in the preclinical state with minimal information available on their proposed mechanism, uses, doses routes, or planned trials. Sixteen of the remaining regimens contain an interferon-based product. The rest include a variety of antimicrobials, corticosteroids, convalescent plasma, and biologics. The Director-General of the WHO, Mr Tedros Adhanom, stated on the 10th of April 2020, that more than 70 countries have joined WHO’s trial to accelerate research on effective treatments and 20 Institutions and companies ‘are racing to develop a vaccine’.
    [Show full text]
  • York and Adams County Taxpayers May Now File Their Earned Income
    YORK ADAMS TAX BUREAU 2010 INSTRUCTIONS YORK ADAMS TAX BUREAU York County Office FOR FILING FORM 214 Adams County Office 1405 N. Duke St., PO Box 15627 900 Biglerville Rd., PO Box 4374 York, PA 17405-0156 Gettysburg, PA 17325 Phone (717) 845-1584 Hours: Mon.- Fri. 8:00 AM – 4:00 PM Phone (717) 334-4000 Fax (717) 854-6376 Fax (717) 337-2565 website: www.yatb.com email: [email protected] online filing: www.palite.org ************************************************************************************************************************************************** ELECTRONIC FILING IS NOW AVAILABLE!! BIG NEWS! York and Adams County taxpayers may now file their earned income returns online! To find out if you are eligible to use the online system, go to our new web site located at http://www.palite.org. ************************************************************************************************************************************************** The York Adams Tax Bureau collects the earned income/compensation tax and the net profits tax for the following school districts and municipalities. If you were a resident of any of the listed taxing authorities for all or any portion of the tax year, you are required to file a tax return with the Bureau, whether or not you had any income. TAX TABLE: TOTAL TAX RATE IS AS INDICATED BELOW NOTE: The * symbol indications portions of these municipalities are in different school districts. ADAMS COUNTY YORK COUNTY YORK COUNTY (cont.) Bermudian Springs School District 1.7% Central York School District 1% School
    [Show full text]
  • People V. Winston: Sports and the Law. INSTITUTION Constitutional Rights Foundation, Los Angeles, CA
    DOCUMENT RESUME ED 458 148 SO 031 449 AUTHOR Degelman, Charles; Hayes, Bill TITLE People v. Winston: Sports and the Law. INSTITUTION Constitutional Rights Foundation, Los Angeles, CA. PUB DATE 1996-00-00 NOTE 23p.; For related lesson plans, see SO 031 448-452. AVAILABLE FROM Constitutional Rights Foundation, 601 South Kingsley Drive, Los Angeles, CA 90005 ($3.95). Tel: 213-487-5590; Fax: 213-386-0459; Web site: http://www.crf-usa.org/. PUB TYPE Guides Classroom Teacher (052) EDRS PRICE MF01/PC01 Plus Postage. DESCRIPTORS Athletic Coaches; *Athletics; Citizenship Education; Conflict Resolution; *Court Litigation; Intermediate Grades; Law Related Education; Role Playing; Secondary Education; *Social Responsibility; Social Studies; *Thinking Skills IDENTIFIERS Assaults; Constitutional Rights Foundation; *Mock Trials ABSTRACT This lesson plan uses students' interest in sports to teach good citizenship. With its focus on rules, responsibility, conflict resolution, and teamwork, the unit emphasizes the development of critical thinking, decision-making, and citizenship skills in young people. This lesson plan is part of a series of fully prepared, interactive classroom lesson plans offered by the Sports and the Law program of the Constitutional Rights Foundation. Each lesson includes detailed teacher instructions, ---background information, and student handouts. This lesson presents a mock trial case of a coach accused of assaulting a referee. Students roleplay attorneys, witnesses, jury members, and court personnel.(BT) Reproductions supplied
    [Show full text]
  • Jury Managers' Manual
    JURY MANAGERS' MANUAL The Jury Managers' Manual is a complete guide to all elements of a trial court juror management system. The subject matter is organized chronologically to match the process by which jurors experience their service. It is the intent of the Office of the State Courts Administrator that the manual be a user-friendly reference source. Effective and efficient juror management will save juror compensation dollars and minimize the inconvenience of those who serve as trial jurors and their employers. Through the efforts of the jury management project, the Florida State Courts System and diligent jury staff, both in the trial court administrator offices and local deputy clerks offices, saved over $3,331,203 in juror compensation costs in fiscal year 1993-94. Achievement and maintenance of the goals of the jury management project cannot continue to be realized without the cooperation of all chief judges, all judges conducting jury trials, trial court administrative staff, and deputy clerks. The Office of the State Courts Administrator has established procedures for monitoring jury system performance in the local trial courts. In addition, the OSCA staff are available to provide technical assistance and training to the trial courts when requested. Any questions about this manual should be directed to Research, Planning & Court Services, Office of the State Courts Administrator, 500 South Duval Street, Supreme Court Building, Tallahassee, Florida 32399-1900. The telephone number is (904) 922-5094, or SUNCOM 292-5094. This manual replaces the Jury System Management Manual issued January 1985. Jury Management Acknowledgement This manual has been developed to assist jury management professionals implement and maintain an efficient and effective trial court jury management system.
    [Show full text]
  • 1:19-Cv-02226 Document #: 1 Filed: 04/01/19 Page 1 of 74 Pageid #:1
    Case: 1:19-cv-02226 Document #: 1 Filed: 04/01/19 Page 1 of 74 PageID #:1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS WELFARE PLAN OF THE INTERNATIONAL UNION OF OPERATING ENGINEERS LOCALS 137, 137A, 137B, 137C, 137R, on behalf of itself Civil Action No.______________ and all others similarly situated, CLASS ACTION Plaintiff, v. JURY TRIAL DEMANDED ABBVIE INC., ABBVIE BIOTECHNOLOGY LTD, and AMGEN INC., Defendants. CLASS ACTION COMPLAINT Case: 1:19-cv-02226 Document #: 1 Filed: 04/01/19 Page 2 of 74 PageID #:2 TABLE OF CONTENTS I. INTRODCUTION ...............................................................................................................1 II. PARTIES .............................................................................................................................3 III. JURISDICTION AND VENUE ..........................................................................................5 IV. THE REGULATORY FRAMEWORK OF BIOLOGICS ..................................................6 A. Cost Concerns Prompt Congress to Enact the Biologics Price Competition and Innovation Act ..............................................................................6 1. New biologic drug approval under the BPCIA ............................................7 2. Biosimilar drug approval under the BPCIA .................................................8 3. Biosimilar entrants’ effect on marketplace ..................................................9 B. Patent Challenges Under the BPCIA .....................................................................11
    [Show full text]
  • Jury Improvement Commission by the People
    “The right of trial by Jury shall be secured to all and remain inviolate forever …” — Nevada Constitution Report of the Supreme Court of Nevada J URY IMPROVEMENT COMMISSION October 2002 Supreme Court of Nevada A. William Maupin, Chief Justice Cliff Young, Vice Chief Justice Robert E. Rose, Justice Miriam Shearing, Justice Deborah A. Agosti, Justice Myron E. Leavitt, Justice Nancy A. Becker, Justice Published by the Administrative Office of the Courts Ron Titus, State Court Administrator Bill Gang, Statewide Court Program Coordinator 201 South Carson Street Carson City, NV 89701 (775) 684-1700 Justice Table of Contents MEMBERS 3 MESSAGES FROM THE CO-CHAIRS Justice Bob Rose 4 Justice Deborah A. Agosti 5 INTRODUCTION 6 SUMMARY OF RECOMMENDATIONS 9 CASE PROCESSING WITH EFFICIENCY A. Minimizing Delays through Pretrial Procedures 15 B. Using Technology in Jury Management 22 SELECTING CITIZENS FOR NEVADA JURIES A. Who is Summoned for Jury Duty and What Source Lists are Used 27 B. Exemptions from Jury Duty 29 C. Juror Compensation 33 D. Frequency of Jury Service 42 E. Citizens Who are Summoned for Jury Duty, But Do Not Respond 45 F. Facilities for Jurors 48 G. Bailiffs—The Court’s Link to the Jury 51 H. Juror Protection 55 EMPOWERING THE JURY A. Mini-Opening Statements and Jury Tutorials 59 B. Instructing Jurors on Relevant Law at the Beginning of Trial 61 C. Jury Notebooks 64 D. Clustering Scientific and Technical Evidence and Permitting Mini-Closing Arguments Following the Presentations 69 E. Jurors Asking Questions 71 a. Minority Report 76 OTHER ISSUES A. Proposed Jurors’ Bill of Rights 80 B.
    [Show full text]
  • Effectiveness of Pfizer-Biontech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
    Morbidity and Mortality Weekly Report Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 Mark W. Tenforde, MD, PhD1; Samantha M. Olson, MPH1; Wesley H. Self, MD2; H. Keipp Talbot, MD2; Christopher J. Lindsell, PhD2; Jay S. Steingrub, MD3; Nathan I. Shapiro, MD4; Adit A. Ginde, MD5; David J. Douin, MD5; Matthew E. Prekker, MD6; Samuel M. Brown, MD7; Ithan D. Peltan, MD7; Michelle N. Gong, MD8; Amira Mohamed, MD8; Akram Khan, MD9; Matthew C. Exline, MD10; D. Clark Files, MD11; Kevin W. Gibbs, MD11; William B. Stubblefield, MD2; Jonathan D. Casey, MD2; Todd W. Rice, MD2; Carlos G. Grijalva, MD2; David N. Hager, MD, PhD12; Arber Shehu, MD12; Nida Qadir, MD13; Steven Y. Chang, MD, PhD13; Jennifer G. Wilson, MD14; Manjusha Gaglani, MBBS15,16; Kempapura Murthy, MPH15; Nicole Calhoun, LMSW, MPA15; Arnold S. Monto, MD17; Emily T. Martin, PhD17; Anurag Malani, MD18; Richard K. Zimmerman, MD19; Fernanda P. Silveira, MD19; Donald B. Middleton, MD19; Yuwei Zhu, MD2; Dayna Wyatt2; Meagan Stephenson, MPH1; Adrienne Baughman2; Kelsey N. Womack, PhD2; Kimberly W. Hart2; Miwako Kobayashi, MD1; Jennifer R. Verani, MD1; Manish M. Patel, MD1; IVY Network; HAIVEN Investigators On April 28, 2021, this report was posted as an MMWR Early ≥65 years. Vaccination is a critical tool for reducing severe Release on the MMWR website (https://www.cdc.gov/mmwr). COVID-19 in groups at high risk. Adults aged ≥65 years are at increased risk for severe outcomes Randomized clinical trials of vaccines that have received an from COVID-19 and were identified as a priority group to EUA in the United States showed efficacy of 94%–95% in receive the first COVID-19 vaccines approved for use under preventing COVID-19–associated illness (4,5).§ However, an Emergency Use Authorization (EUA) in the United States hospitalization is a rare outcome among patients with (1–3).
    [Show full text]
  • 2019 Annual Report on Form 10-K
    2 0 1 9 A n n u a l R e p o r t o n AbbVie F o r m 1 0 - K 2 0 2 0 . N Here Now o t i c e o f A n n u a l M e e t i n g & P r o x y S t a t e m e n t 2019 Annual Report on Form 10-K 2020 Notice of AbbVie 1 North Waukegan Road, North Chicago, IL 60064 U.S.A. Annual Meeting Copyright© 2020 AbbVie. All rights reserved. abbvie.com & Proxy Statement 3033_Cover.indd 1 3/18/20 6:36 PM AbbVie’s Commitment to Corporate Responsibility Stockholder Information We strive to make a remarkable impact on patients and drive sustainable growth by discovering and AbbVie Inc. Corporate Headquarters delivering a consistent stream of innovative medicines that address serious health problems. 1 North Waukegan Road North Chicago, IL 60064 IIn accordance wiitth our Priinciiplles:: 847.932.7900 abbvie.com Transforming lives Embracing diversity and inclusion Acting with integrity Serving the community Investor Relations Driving innovation Dept. ZZ05, AP34 Our Corporate Responsibility priorities are: Corporate Secretary Dept. V364, AP34 Using our expertise to Stewarding our ethical and Supporting long-term Stock Listing improve health sustainable business community strength The ticker for AbbVie’s common stock Creating real health improvement is We recognize that health is of The health of our business is is ABBV. The principal market for our mission and the premise of our fundamental importance to all people. intertwined with that of our communities.
    [Show full text]